VEGF Human, CHO
Description
Definition and Production
VEGF Human, CHO refers to the human VEGF-A165 isoform synthesized through recombinant DNA technology in CHO cell lines. These mammalian cells enable proper protein folding and glycosylation patterns critical for receptor binding .
Production Process:
-
Expression System: CHO cells modified with human VEGF165 cDNA
-
Purification: Two-step chromatography achieving 48% recovery
Key Domains:
| Domain | Function |
|---|---|
| Receptor-binding | Binds VEGFR1/VEGFR2 |
| Heparin-binding | Enhances extracellular matrix retention |
In Vitro Performance:
-
EC50: 0.29 ng/mL in human retinal microvascular endothelial cell (HRMVEC) proliferation assays
-
Receptor Activation: Binds VEGFR2 with high affinity (Kd = 75–125 pM)
In Vivo Efficacy (Rabbit Model):
| Parameter | CHO-Derived VEGF | E. coli-Derived VEGF |
|---|---|---|
| Retinal Leakage (400 ng dose) | 0.24 AU | 0.37 AU |
| Maximal Effect Dose | ≥800 ng | ≥400 ng |
CHO vs. E. coli Expression:
| Feature | CHO-Derived VEGF | E. coli-Derived VEGF |
|---|---|---|
| Glycosylation | Present | Absent |
| In Vivo Potency | Lower | Higher |
| Production Cost | Higher | Lower |
Therapeutic Applications
-
Ischemic Diseases: Promotes collateral vessel formation in myocardial infarction
-
Wound Healing: Accelerates vascularization in diabetic ulcers
-
Safety Profile: No nephrotoxicity observed at therapeutic doses (≤200 mg/kg in rats)
Challenges and Future Directions
Product Specs
Product Science Overview
Vascular Endothelial Growth Factor (VEGF) is a sub-family of growth factors, specifically the platelet-derived growth factor family of cystine-knot growth factors . VEGF plays a crucial role in both vasculogenesis (the formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature) . It is a key regulator of angiogenesis and is central to processes such as tumor growth and metastatic dissemination .
Human recombinant VEGF, particularly VEGF165, is a bioactive form that has been extensively studied for its role in promoting angiogenesis and vascular permeability . The recombinant form is produced using various expression systems, including Chinese Hamster Ovary (CHO) cells, which are commonly used for the production of therapeutic proteins due to their ability to perform post-translational modifications similar to those in humans .
The production of human recombinant VEGF involves several steps:
- Cloning and Expression: The gene encoding VEGF is cloned into an expression vector, which is then introduced into CHO cells . These cells are cultured under specific conditions to express the VEGF protein.
- Purification: The expressed VEGF protein is purified using techniques such as affinity chromatography . This step ensures that the protein is isolated in a highly pure form.
- Characterization: The purified protein is characterized to confirm its identity, purity, and biological activity .
VEGF mediates its effects by binding to specific receptors on the surface of endothelial cells, primarily VEGFR-1 and VEGFR-2 . This binding activates a cascade of signaling pathways that promote endothelial cell proliferation, migration, and new blood vessel formation . The biological activity of recombinant VEGF can be assessed using various assays, such as the Chicken chorioallantoic membrane assay and wound-healing migration assays .
Recombinant VEGF has significant therapeutic potential. It is used in research to study angiogenesis and in clinical settings to promote wound healing and treat conditions such as ischemic heart disease and peripheral artery disease . Additionally, VEGF inhibitors are used in cancer therapy to inhibit tumor growth by blocking angiogenesis .
